Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? - PubMed (original) (raw)

Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?

David M Kent et al. Stroke. 2003 Feb.

Abstract

Background and purpose: Recombinant tissue plasminogen activator (rtPA) has been demonstrated to improve outcomes in acute ischemic stroke when delivered within 3 hours of symptom onset. However, the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS B) trial, in which patients were treated mostly between 3 and 5 hours after symptom onset, found no overall benefit from rtPA. We hypothesized that a subgroup of patients at low risk for thrombolysis-related intracranial hemorrhage, identifiable on the basis of pretreatment clinical variables, may benefit even when treated after 3 hours, despite the overall results of the trial.

Methods: Using an independently derived multivariate model that predicts the risk of thrombolysis-related intracranial hemorrhage in patients receiving tPA for acute myocardial infarction (based on 6 easily obtainable clinical characteristics), we stratified patients in the ATLANTIS B trial into low-, intermediate-, and high-risk tertiles. We examined outcomes in the prespecified low-risk subgroup using a global test of significance across 4 outcome scales.

Results: Despite having a similar average baseline stroke severity and median time to treatment (270 minutes), patients in the prespecified low-risk group (n=194) were significantly less likely to have a symptomatic intracranial hemorrhage than other patients in the trial (2.2% versus 9.2%, P=0.03). Although there was no treatment effect for rtPA in the overall trial, a consistent trend favoring rtPA therapy (a 5% to 12% absolute treatment benefit) was found across 4 different stroke scales in the prespecified low-risk group (P=0.10). The treatment-benefit-by-risk interaction was significant (P=0.03).

Conclusions: Use of a multivariate index based on clinical variables is a promising approach to assist in the selection of patients with a favorable risk-benefit profile for thrombolytic therapy beyond 3 hours.

PubMed Disclaimer

Cited by

Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.
Hayward RA, Kent DM, Vijan S, Hofer TP. Hayward RA, et al. BMC Med Res Methodol. 2006 Apr 13;6:18. doi: 10.1186/1471-2288-6-18. BMC Med Res Methodol. 2006. PMID: 16613605 Free PMC article.
Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death.
Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D, Stanworth SJ, Curley A, Onland W, Steyerberg EW, de Kort E, d'Haens EJ, Hulzebos CV, Huisman EJ, de Boode WP, Lopriore E, van der Bom JG; PlaNeT2 and MATISSE collaborators. Fustolo-Gunnink SF, et al. Blood. 2019 Dec 26;134(26):2354-2360. doi: 10.1182/blood.2019000899. Blood. 2019. PMID: 31697817 Free PMC article. Clinical Trial.
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.
Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Kent DM, et al. Trials. 2010 Aug 12;11:85. doi: 10.1186/1745-6215-11-85. Trials. 2010. PMID: 20704705 Free PMC article.
No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals.
Gabler NB, Duan N, Raneses E, Suttner L, Ciarametaro M, Cooney E, Dubois RW, Halpern SD, Kravitz RL. Gabler NB, et al. Trials. 2016 Jul 16;17(1):320. doi: 10.1186/s13063-016-1447-5. Trials. 2016. PMID: 27423688 Free PMC article.
Thrombolysis for acute ischaemic stroke.
Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Wardlaw JM, et al. Cochrane Database Syst Rev. 2014 Jul 29;2014(7):CD000213. doi: 10.1002/14651858.CD000213.pub3. Cochrane Database Syst Rev. 2014. PMID: 25072528 Free PMC article. Review.

Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? - PubMed (original) (raw)